Methods	Five-week randomised, double-blind, multicentre study.
Participants	In- and outpatients fulfilling Research Diagnostic Criteria for unipolar major depressive episode, with a score of at least 17 on the HDRS-17 and 8 on the Raskin. Age range: 18-65 years. Exclusion criteria: serious non-stabilised somatic illness, drug or alcohol abuse, evidence of dementia, depressive schizophrenic, serious suicide risk, concurrent administration of other psychotropic drug (with the exclusion of benzodiazepines or chloral hydrate for insomnia or anxiety)
Interventions	Fluoxetine: 24 participants. Maprotiline : 22 participants. Fluoxetine dose range: 20-60 mg/day. Maprotiline dose range: 50-150 mg/day.
Outcomes	Hamilton Rating Scale for Depression, Raskin Depression Scale, Covi Axxiety Scale, PGI, CGI
Notes	Funding: unclear
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear